Clinical Trials Sponsored by Otsuka Pharmaceutical Europe Ltd

Total 286 results

Otsuka Pharmaceutical Europe Ltd

Completed

Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain (PROSIGO)

Schizophrenia

Spain
Otsuka Pharmaceutical Europe Ltd

Completed

An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain (ALGA)

Hyponatremia | Syndrome of Inappropriate ADH (SIADH) Secretion

Spain
Otsuka Pharmaceutical Europe Ltd

Completed

An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy (ASSERT)

Cancer | Hyponatremia | Syndrome of Inappropriate ADH (SIADH) Secretion

Italy
Otsuka Pharmaceutical Europe Ltd

Completed

An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH (SAMPLE)

Hyponatremia | Syndrome of Inappropriate ADH (SIADH) Secretion

Germany, Spain
Otsuka Pharmaceutical Europe Ltd

Completed

Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy (DOMINO)

Schizophrenia

Italy
Otsuka Pharmaceutical Europe Ltd

Unknown

A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe (ACQUIRE)

Autosomal Dominant Polycystic Kidney Disease

Spain, United Kingdom, Germany, France, Belgium, Switzerland, Austria
Otsuka Pharmaceutical Europe Ltd

Completed

Adacolumn in Refractory UC Patients Trial (ART)

Ulcerative Colitis, Active Moderate

France
Otsuka Pharmaceutical Europe Ltd
H. Lundbeck A/S

Unknown

Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia

Schizophrenia

Spain, Italy, France, Germany
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Pharmacokinetics of Probucol and Cilostazol

Healthy

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects. (OPS-2071Ph1)

Healthy

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

Tourette's Disorder | Chronic Motor or Vocal Tic Disorder

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Unknown

Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients

Oral Mucositis

Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Taiwan, Korea, Republic of, Japan
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

Solid Tumor

Korea, Republic of
Assistance Publique - Hôpitaux de Paris
Otsuka Pharmaceutical Europe Ltd

Unknown

Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) (TOLVATHIRST)

Healthy Volunteers

France
Otsuka Pharmaceutical, Inc., Philippines
Otsuka Pharmaceutical Co., Ltd.

Terminated

Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients

Pulmonary Disease, Chronic Obstructive

Philippines
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma (MM)

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

Japan
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia

Hyper-low-density Lipoprotein (LDL) Cholesterolemia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

Migraine

Japan
Otsuka Pharmaceutical Co., Ltd.

Withdrawn

A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia

Schizophrenia
Otsuka Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg

Healthy Adult Male

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer

Stomach Ulcer

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I Study of OPC-61815

Congestive Heart Failure

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

China, Japan, Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Terminated

A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects

Healthy Adult Male

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Trial of OPC-34712 in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients

Gastroesophageal Reflux Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Terminated

Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Agitation Associated With Dementia of the Alzheimer's Type

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries

Clostridium Difficile Infection

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis

Chronic Renal Failure

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

Ocular Hypertension | Glaucoma

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Exploratory Study of OPC-12759 Ophthalmic Suspension

Keratoconjunctival Epithelial Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome (RLS)

Idiopathic Restless Legs Syndrome
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

Early Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

Bipolar I Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-response Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

Bipolar I Disorder

Taiwan, Korea, Republic of, Japan, China
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

Cardiac Edema (CHF)

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

Migraine Disorders

Japan

3

Subscribe